Key result
Adding cilostazol resolves subacute stent thrombosis linked to ticlopidine resistance in a case report.
Why the study?
Subacute stent thrombosis related to ticlopidine resistance is a clinical concern requiring detailed case characterization.
Case Report (n=1)
Demonstrates a case of subacute stent thrombosis directly linked to ticlopidine resistance, emphasizing the importance of adequate platelet inhibition after stenting.
Answers are grounded in this paper and cite their sources.
Alerts to possible ticlopidine resistance post-stenting; leaves open whether platelet testing should guide therapy.
A 79-year-old man underwent stent implantation from the proximal site to the left main trunk with one bare metal stent after rotation atherectomy. He received 200 mg/day ticlopidine and 200 mg/day aspirin from 2 days pre-stenting. Subacute thrombosis occurred 5 days after coronary stenting. We performed a test of platelet aggregation one month after the commencement of dual antiplatelet therapy and the test showed no response to ticlopidine in this case. An increased dose of ticlopidine was not effective for suppressing platelet aggregation. We report a case of subacute stent thrombosis which is related to ticlopidine resistance.
No takes yet. Share an insight, caveat, or question.
Fuchigami et al. (2006) conducted a case report in Subacute stent thrombosis (n=1). Ticlopidine was evaluated on Platelet aggregation. A 79-year-old man developed subacute stent thrombosis 5 days after coronary stenting due to ticlopidine resistance, which was not overcome by increasing the dose but resolved after adding cilostazol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: